D-Dimer Levels in Lung Adenocarcinoma as a predictor of Chemotherapy Response Based on RECIST

<bold>Introduction:</bold> Lung cancer is characterized by rapid progression and high invasive ability, it is depended on the ability of cancer cells to develop neoangiogenesis and metastasis. D-dimer is a marker of fibrinolysis and its concentration in blood can reflect the degree of activation of the coagulation system and fibrinolytic system. This study aims to look at fibrin degradation products (D-Dimer) as a specific marker for chemotherapy response in adenocarcinoma cancer treated with first-line chemotherapy. <bold>Methods:</bold> After 3 cycles of first-line chemotherapy, the response to chemotherapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) and D-Dimers Level. The relationship between D-Dimer levels and RECIST was analyzed with Kruskal Wallis test. <bold>Results:</bold> This study recruited 30 Adenocarcinoma lung cancer patients. After three cycles of first-line chemotherapy, patients divided into 3 groups (10 Partial Response (33.3%), Stable Disease 3 (10%), and 17 Progressive Disease 56.7%)). The Kruskal-Wallis test showed significant relationship between D-Dimer levels and chemotherapy response based on RECIST (p<0.05). The mean rank partial response was 8.30, Stable Disease was 6.30, and Progressive Disease was 21.35. Post Hoc test showed there were significant difference in D-Dimer levels in RECIST Progressive Disease with Stable Disease and Progressive Disease with Partial Response. However, there was no significant difference in D-Dimer levels in RECIST Stable Disease and Partial Response. <bold>Conclusions:</bold> This study showed fibrin degradation products (D-dimer) as a specific marker for chemotherapy response in NSCLC patients treated with 1st line chemotherapy.